AdaptHealth Corp 8-K, filed Jul 7, 2026
AdaptHealth Corp. (AHCO)
About this 8-K
AdaptHealth Corp filed this 8-K on July 7, 2026, reporting on events of July 6, 2026.
Items reported
- Item 7.01: Regulation FD disclosure
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) | |
| ( |
||
(Registrant’s telephone number, including area code) |
||
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 7.01. Regulation FD Disclosure. |
On July 6, 2026, AdaptHealth LLC (the “Issuer”), an indirect wholly-owned subsidiary of AdaptHealth Corp. (the “Company”), issued a notice of redemption for all of its outstanding 6.125% Senior Notes due 2028 (the “Notes”) in an aggregate principal amount of $325,000,000 (the “Redemption”), at a redemption price equal to 100% of the aggregate principal amount of the Notes to be redeemed, plus accrued and unpaid interest on such Notes to, but not including, the redemption date (the “Redemption Price”). The Redemption will be conditioned upon receipt by the Issuer or any of its subsidiaries of the net proceeds of a borrowing under its existing delayed draw term loan facility in an aggregate principal amount sufficient to pay the Redemption Price (the “Redemption Condition”). The date of redemption is expected to be August 1, 2026 (the “Redemption Date”), subject to the satisfaction of the Redemption Condition. Pursuant to the indenture governing the Notes, payment of the Redemption Price is expected to occur on the next succeeding business day following the Redemption Date, which is August 3, 2026, and no interest will accrue for the period from and after the Redemption Date.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 7, 2026
| AdaptHealth Corp. | |||
| By: | /s/ Jason Clemens | ||
| Name: | Jason Clemens | ||
| Title: | Chief Financial Officer | ||